These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 26891981)

  • 1. Recent developments in using mechanistic cardiac modelling for drug safety evaluation.
    Davies MR; Wang K; Mirams GR; Caruso A; Noble D; Walz A; Lavé T; Schuler F; Singer T; Polonchuk L
    Drug Discov Today; 2016 Jun; 21(6):924-38. PubMed ID: 26891981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive in vitro Proarrhythmia Assay, a novel in vitro/in silico paradigm to detect ventricular proarrhythmic liability: a visionary 21st century initiative.
    Cavero I; Holzgrefe H
    Expert Opin Drug Saf; 2014 Jun; 13(6):745-58. PubMed ID: 24845945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive In Vitro Proarrhythmia Assay (CiPA) Update from a Cardiac Safety Research Consortium / Health and Environmental Sciences Institute / FDA Meeting.
    Strauss DG; Gintant G; Li Z; Wu W; Blinova K; Vicente J; Turner JR; Sager PT
    Ther Innov Regul Sci; 2019 Jul; 53(4):519-525. PubMed ID: 30157676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative Systems Pharmacology Models for a New International Cardiac Safety Regulatory Paradigm: An Overview of the Comprehensive In Vitro Proarrhythmia Assay In Silico Modeling Approach.
    Li Z; Garnett C; Strauss DG
    CPT Pharmacometrics Syst Pharmacol; 2019 Jun; 8(6):371-379. PubMed ID: 31044559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - Update on progress.
    Colatsky T; Fermini B; Gintant G; Pierson JB; Sager P; Sekino Y; Strauss DG; Stockbridge N
    J Pharmacol Toxicol Methods; 2016; 81():15-20. PubMed ID: 27282641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of disease state on arrhythmic event detection by action potential modelling in cardiac safety pharmacology.
    Christophe B; Crumb WJ
    J Pharmacol Toxicol Methods; 2019; 96():15-26. PubMed ID: 30580044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 13th Annual Meeting of the Safety Pharmacology Society: focus on novel technologies and safety pharmacology frontiers.
    Cavero I
    Expert Opin Drug Saf; 2014 Sep; 13(9):1271-81. PubMed ID: 25054438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A New Perspective in the Field of Cardiac Safety Testing through the Comprehensive In Vitro Proarrhythmia Assay Paradigm.
    Fermini B; Hancox JC; Abi-Gerges N; Bridgland-Taylor M; Chaudhary KW; Colatsky T; Correll K; Crumb W; Damiano B; Erdemli G; Gintant G; Imredy J; Koerner J; Kramer J; Levesque P; Li Z; Lindqvist A; Obejero-Paz CA; Rampe D; Sawada K; Strauss DG; Vandenberg JI
    J Biomol Screen; 2016 Jan; 21(1):1-11. PubMed ID: 26170255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. General Principles for the Validation of Proarrhythmia Risk Prediction Models: An Extension of the CiPA In Silico Strategy.
    Li Z; Mirams GR; Yoshinaga T; Ridder BJ; Han X; Chen JE; Stockbridge NL; Wisialowski TA; Damiano B; Severi S; Morissette P; Kowey PR; Holbrook M; Smith G; Rasmusson RL; Liu M; Song Z; Qu Z; Leishman DJ; Steidl-Nichols J; Rodriguez B; Bueno-Orovio A; Zhou X; Passini E; Edwards AG; Morotti S; Ni H; Grandi E; Clancy CE; Vandenberg J; Hill A; Nakamura M; Singer T; Polonchuk L; Greiter-Wilke A; Wang K; Nave S; Fullerton A; Sobie EA; Paci M; Musuamba Tshinanu F; Strauss DG
    Clin Pharmacol Ther; 2020 Jan; 107(1):102-111. PubMed ID: 31709525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biophysics and Molecular Biology of Cardiac Ion Channels for the Safety Pharmacologist.
    Pugsley MK; Curtis MJ; Hayes ES
    Handb Exp Pharmacol; 2015; 229():149-203. PubMed ID: 26091640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive in vitro Proarrhythmia Assay (CiPA): Pending issues for successful validation and implementation.
    Cavero I; Guillon JM; Ballet V; Clements M; Gerbeau JF; Holzgrefe H
    J Pharmacol Toxicol Methods; 2016; 81():21-36. PubMed ID: 27233533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of an In Silico Mechanistic Model for Proarrhythmia Risk Prediction Under the CiPA Initiative.
    Li Z; Ridder BJ; Han X; Wu WW; Sheng J; Tran PN; Wu M; Randolph A; Johnstone RH; Mirams GR; Kuryshev Y; Kramer J; Wu C; Crumb WJ; Strauss DG
    Clin Pharmacol Ther; 2019 Feb; 105(2):466-475. PubMed ID: 30151907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proarrhythmia liability assessment and the comprehensive in vitro Proarrhythmia Assay (CiPA): An industry survey on current practice.
    Authier S; Pugsley MK; Koerner JE; Fermini B; Redfern WS; Valentin JP; Vargas HM; Leishman DJ; Correll K; Curtis MJ
    J Pharmacol Toxicol Methods; 2017 Jul; 86():34-43. PubMed ID: 28223123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uncertainty Quantification Reveals the Importance of Data Variability and Experimental Design Considerations for
    Chang KC; Dutta S; Mirams GR; Beattie KA; Sheng J; Tran PN; Wu M; Wu WW; Colatsky T; Strauss DG; Li Z
    Front Physiol; 2017; 8():917. PubMed ID: 29209226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early drug development: assessment of proarrhythmic risk and cardiovascular safety.
    Lester RM; Olbertz J
    Expert Rev Clin Pharmacol; 2016 Dec; 9(12):1611-1618. PubMed ID: 27718759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities.
    Koci B; Luerman G; Duenbostell A; Kettenhofen R; Bohlen H; Coyle L; Knight B; Ku W; Volberg W; Woska JR; Brown MP
    Toxicol Appl Pharmacol; 2017 Aug; 329():121-127. PubMed ID: 28546047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology-based toxicity assessment: towards quantitative risk prediction in humans.
    Sahota T; Danhof M; Della Pasqua O
    Mutagenesis; 2016 May; 31(3):359-74. PubMed ID: 26970519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CiPA: Ongoing testing, future qualification procedures, and pending issues.
    Cavero I; Holzgrefe H
    J Pharmacol Toxicol Methods; 2015; 76():27-37. PubMed ID: 26159293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 1: goals, properties of the PhRMA dataset, and comparison with literature datasets.
    Poulin P; Jones HM; Jones RD; Yates JW; Gibson CR; Chien JY; Ring BJ; Adkison KK; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Ku MS
    J Pharm Sci; 2011 Oct; 100(10):4050-73. PubMed ID: 21523782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A temperature-dependent in silico model of the human ether-à-go-go-related (hERG) gene channel.
    Li Z; Dutta S; Sheng J; Tran PN; Wu W; Colatsky T
    J Pharmacol Toxicol Methods; 2016; 81():233-9. PubMed ID: 27178106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.